Inovio Receives FDA Accelerated Approval for RRP Treatment VOCERYQ
INO Inovio Pharmaceuticals Inc
$1.45 -3.97%
View chart & analysis → - 1The U.S. Food and Drug Administration (FDA) has granted accelerated approval for VOCERYQ, a treatment for RRP in adults.
- 2Among patients who required three or more surgeries in the previous 12 months, 7 patients, or 27%, achieved a complete response where no surgical removal of papillomas was required for 12 months after treatment.
- 3Inovio plans to prepare VOCERYQ for ordering and delivery within approximately 60 days.
So what's the key point?
The U.S. government has quickly approved a new treatment from Inovio. Because results showed that 27 percent of patients recovered without surgery, the medicine will be available for sale soon.
Source InvestorsHub +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.